Lanean...
The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
As many patients ultimately relapse after chimeric antigen receptor (CAR) T-cell therapy, identification of alternative targets is currently being evaluated. Substantial research efforts are underway to develop new targets. The transferrin receptor (TfR) is prevalently expressed on rapidly prolifera...
Gorde:
| Argitaratua izan da: | Front Immunol |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Frontiers Media S.A.
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8039461/ https://ncbi.nlm.nih.gov/pubmed/33854512 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.652924 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|